Intellia Therapeutics
NTLA
85 hedge funds and large institutions have $269M invested in Intellia Therapeutics in 2017 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 12 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 10
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
54% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $778K
14% more capital invested
Capital invested by funds: $236M → $269M (+$33M)
12% more funds holding
Funds holding: 76 → 85 (+9)
0.19% more ownership
Funds ownership: 46.47% → 46.66% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.2M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.74M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.33M |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
+$1.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.8M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$4.66M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$4.23M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$2.11M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.12M |
NTLA Hedge Fund Activity: Q2 2017 in Review
85 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2017, worth a combined $269M — up 14% from $236M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NTLA positions and 12 closed out — a net gain of 9 holders — while 36 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was Fidelity Investments, cutting an estimated $10.8M.
- 85 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2017, up from 76 in Q1 2017.
- Funds reported $269M of Intellia Therapeutics stock for Q2 2017, up 14% quarter-over-quarter.
- 21 funds opened new Intellia Therapeutics positions in Q2 2017 and 12 closed out, a net change of +9 holders.
- The largest Intellia Therapeutics buyer in Q2 2017 was BlackRock, an estimated $10.2M added.
- The largest Intellia Therapeutics seller in Q2 2017 was Fidelity Investments, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2017.